[1,2,4]triazolopyridines and their use as phosphodiesterase inhibitors
The present invention relates to novel [1,2,4]triazolopyridine compounds with phosphodiesterase inhibitory activity, as well as to their use as therapeutic agents in the treatment of inflammatory diseases and conditions.
1. A method of treating dermal diseases or conditions, which method comprises the step of administering to person suffering from said disease or condition a therapeutically effective amount of tert-butyl 1-[8-methoxy-5-(1-oxo-3H-isobenzofuran-5-yl)-[1,2,4]triazolo[1,5-a]pyridin-2-yl]cyclopropanecarboxylate, optionally together with a pharmaceutically acceptable carrier or one or more excipients, wherein the dermal disease or condition is selected from the group consisting of dermatitis, atopic dermatitis, seborrheic dermatitis, contact dermatitis, psoriasis, acne, pruritis, eczema, COPD and asthma.